Doctor of Philosophy

Elastrin Therapeutics Announces Newly Formed Scientific Advisory Board

Retrieved on: 
Monday, January 17, 2022 - 11:40am
Biotechnology, Pharmaceutical, Health, Other Health, Linda, Clemson University, EDTA, Green College, Hotel des Indes (The Hague), VP, MAA, Industry, Therapy, Hospital, Grünenthal, LLC, Yuri, Health authority, NDA, Investment, Technology, Ageing, Conference, Pangborn Sensory Science Symposium, CTAS, Degenerative disease, Corporation, MBA, Cardiovascular disease, Health, Associate, Doctor of Philosophy, NICE, VC, Head, Elastin, United States Air Force Scientific Advisory Board, Patient, CMO, Chronic kidney disease, Reader, Mentorship, University, III, Board, Harvard Medical School, Winnipeg Regional Health Authority, Seminal vesicles, CEO, University of California, San Diego, MD, Calcification, Pharmaceutical industry, Management, Research, Brigham, Pediatrics, Medicine

Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the formation of its Scientific Advisory Board.

Key Points: 
  • Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the formation of its Scientific Advisory Board.
  • We are fortunate to work with such an amazing group of medical scientists, cardiovascular experts and pharma executives on our Scientific Advisory Board, said Dr. Matthias Breugelmans, CEO of Elastrin Therapeutics.
  • Elastrin is a prime example of what Kizoo is looking for in its investments: Not delaying an age-related disease but reversing it, said Patrick Burgermeister, Partner at Kizoo Technology Capital and member of Elastrin Therapeutics Board of Directors.
  • Elastrin Therapeutics Scientific Advisory Board is comprised of:
    Prof. Charles O'Neill, MD: Dr. ONeill has had an active basic and clinical research program in vascular calcification for the past 20 years and has published over 45 articles on this subject.

Brazil’s SENAI CIMATEC Doses First Healthy Volunteers in Phase 1 trial of HDT Bio’s RNA COVID-19 Vaccine

Retrieved on: 
Monday, January 17, 2022 - 10:30am
Research, Infectious Diseases, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, All-China Federation of Industry and Commerce, Vaccination, Research, Technology, Ministry, Safety, Vaccine, Clinical trial, Incidence, Biotechnology, RNA, COVID-19, Population, Adult, Volunteering, Phase II, Health, Infection, Industry, Education, HDT, Doctor of Philosophy, Therapy, Immune system, Engineering, Principal, SENAI, Partnership, Trial of the century, Science

SENAI CIMATEC will conduct the clinical trial under the name Vaccine RNA MCTI-CIMATEC-HDT.

Key Points: 
  • SENAI CIMATEC will conduct the clinical trial under the name Vaccine RNA MCTI-CIMATEC-HDT.
  • The first was in India with our partner Gennova Biopharmaceuticals which has moved the vaccine into Phase 2 and Phase 3 trials.
  • HDT Bio has other partnerships for its RNA COVID-19 vaccine, including in South Korea and China.
  • HDT Bios innovative vaccine, which also will undergo a Phase 1 trial in the U.S. , uses its proprietary lipid nanoparticle carrier system for delivery of RNA.

Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B

Retrieved on: 
Monday, January 17, 2022 - 10:08am
Research, Gannex, Liver cancer, HKEX, Cornerstone, Acne, CHB, Investigational New Drug, Prevalence, PD-1, RNA, COVID-19, GBM, Safety, Hong Kong Stock Exchange, NASH, Hepatitis B, Nas, CDC classification system for HIV infection, Hepatitis C, WHO, OBI Pharma, Inc., FXR, Doctor of Philosophy, HBsAg, Food, World Health Organization, Phase, Interim, FDA, Patient, Institute of Liver and Biliary Sciences, World, Association, HBV, IIB, DHHS, American Association, Pegasys, R, American Association for Cancer Research, AASLD, RNA polymerase II, CEO, Degenerative disease, IND, Hepatitis B virus, HIV/AIDS, FASN, PBC, Food and Drug Administration, PD-L1, THR, United States Department of Health and Human Services, Vaccine, Pharmaceutical industry, Medical device, Cancer

HANGZHOU and SHAOXING, China, Jan. 17, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today the Investigational New Drug (IND) application approval by U.S. Food and Drug Administration (FDA) and initiation of global development of ASC22 (Envafolimab), a first-in-class, subcutaneously administered PD-L1 antibody for functional cure of chronic hepatitis B (CHB).

Key Points: 
  • Such inclusion is a singular honor and indicates the high level with which the AASLD review committee regards Ascletis' research in CHB functional cure.
  • "ASC22 (Envafolimab) U.S. IND approval enables us to initiate U.S. and global clinical trials for CHB functional cure.
  • Viral Diseases: (1) Hepatitis B Virus (functional cure): focus on breakthrough therapies for CHB functional cure with a subcutaneously-injected PD-L1 antibody ASC22 and Pegasys as cornerstone drugs.
  • (3) HIV/AIDS: ASC22, an immune therapy to restore HIV-specific immune responses and eventually lead to a functional cure of HIV-infected patients.

Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B

Retrieved on: 
Monday, January 17, 2022 - 9:53am
Research, Gannex, Liver cancer, HKEX, Cornerstone, Acne, CHB, Investigational New Drug, Prevalence, PD-1, RNA, COVID-19, GBM, Safety, Hong Kong Stock Exchange, NASH, Nas, WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents, Hepatitis C, WHO, OBI Pharma, Inc., FXR, Doctor of Philosophy, HBsAg, Food, World Health Organization, Interim, FDA, Patient, Institute of Liver and Biliary Sciences, World, Association, HBV, IIB, DHHS, American Association, Pegasys, R, American Association for Cancer Research, AASLD, RNA polymerase II, CEO, Degenerative disease, IND, Hepatitis B virus, HIV/AIDS, FASN, PBC, Food and Drug Administration, PD-L1, THR, United States Department of Health and Human Services, Pharmaceutical industry, Vaccine, Medical device, Cancer

Such inclusion is a singular honor and indicates the high level with which the AASLD review committee regards Ascletis' research in CHB functional cure.

Key Points: 
  • Such inclusion is a singular honor and indicates the high level with which the AASLD review committee regards Ascletis' research in CHB functional cure.
  • "ASC22 (Envafolimab) U.S. IND approval enables us to initiate U.S. and global clinical trials for CHB functional cure.
  • Viral Diseases: (1) Hepatitis B Virus (functional cure): focus on breakthrough therapies for CHB functional cure with a subcutaneously-injected PD-L1 antibody ASC22 and Pegasys as cornerstone drugs.
  • (3) HIV/AIDS: ASC22, an immune therapy to restore HIV-specific immune responses and eventually lead to a functional cure of HIV-infected patients.

Pharmaron Appoints Dr. Antony Davies as Senior Vice President, UK CMC

Retrieved on: 
Monday, January 17, 2022 - 12:00am
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, MSD, Doctor of Philosophy, Research, East Anglia, CMC, D, Cass Business School, MBA, Chemistry, CEO, Process, Solution, GMP, CGT, Industry, CGMP, Control, Process chemistry, API, Drug discovery, Senior, University of East Anglia, Management, Fine chemical, Hoddesdon

Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (Pharmaron) today announced the appointment of Dr. Antony (Tony) Davies as Senior Vice President, UK CMC, effective January 10, 2022.

Key Points: 
  • Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (Pharmaron) today announced the appointment of Dr. Antony (Tony) Davies as Senior Vice President, UK CMC, effective January 10, 2022.
  • The UK Chemistry, Manufacturing and Control (CMC) business includes operations in Hoddesdon and Cramlington, UK.
  • Tony has been Senior Vice President, Process R&D, since 2019, having been promoted from Vice President, Process Chemistry, a post he held since Pharmaron acquired the MSD Hoddesdon site in 2016.
  • The UK CMC business currently includes operations in Hoddesdon and Cramlington, UK.

Innovative Solutions & Support, Inc. Appoints Shahram Askarpour as Chief Executive Officer

Retrieved on: 
Friday, January 14, 2022 - 9:30pm
Mobile, Wireless, Technology, Security, Air, Transport, Aerospace, Software, Manufacturing, Networks, Data Management, GE Aviation Systems, Middlesex University, Technology, SEC, Electrical engineering, Electricity, Smiths Group, NASDAQ, Automation, Smiths, Wharton School of the University of Pennsylvania, Instrumentation, Flight management system, GPS, Leadership, Brunel University London, Original equipment manufacturer, Company, FMS, Doctor of Philosophy, Carnegie Mellon University, ISSC, BAE Systems Avionics, Wendell Pritchett, United Kingdom, Director, Board, Management, Engineering, Isambard Kingdom Brunel

Innovative Solutions & Support, Inc. (NASDAQ: ISSC) today announces that the Board of Directors has appointed Dr. Shahram Askarpour, the Companys President, to the role of Chief Executive Officer.

Key Points: 
  • Innovative Solutions & Support, Inc. (NASDAQ: ISSC) today announces that the Board of Directors has appointed Dr. Shahram Askarpour, the Companys President, to the role of Chief Executive Officer.
  • Dr. Askarpours appointment follows yesterdays announcement of the untimely passing of former IS&S Chairman and CEO Geoffrey S. M. Hedrick.
  • Since founding IS&S in 1988, Geoff built up a strong and reliable management team to solidify our company for the future.
  • About Innovative Solutions & Support, Inc.
    Headquartered in Exton, Pa., Innovative Solutions & Support, Inc. ( www.innovative-ss.com ) is a systems integrator that designs and manufactures flight guidance and cockpit display systems for Original Equipment Manufacturers (OEMs) and retrofit applications.

U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis

Retrieved on: 
Friday, January 14, 2022 - 8:30pm
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Janus, Atopic dermatitis, New Drug Application, NDA, Patient, Food and Drug Administration, Week, Janus kinase 1, Pfizer, Dupilumab, Inc., Psoriasis Area and Severity Index, NYSE, Rash, Common, Adult, Nausea, CEO, JADE, Disease, Kidney failure, CYP2C19, AD, Department, George Washington University School of Medicine & Health Sciences, Headache, PFE, Inflammation, Outline of health sciences, Skin, Pain, JAK1, CYP, MD, Dermatitis, Food, Immunology, FDA, EASI, MPH, IGA, Pharmaceutical industry, P450, Safety, Doctor of Philosophy

Atopic dermatitis is so much more than just a rash, and it goes beyond the surface of the skin.

Key Points: 
  • Atopic dermatitis is so much more than just a rash, and it goes beyond the surface of the skin.
  • We appreciate Pfizers commitment to this resilient patient community and eagerly await the positive impact CIBINQO could have on the treatment landscape for moderate-to-severe atopic dermatitis.
  • Five clinical trials in the CIBINQO JAK1 Atopic Dermatitis Efficacy and Safety (JADE) global development program were included in the New Drug Application (NDA) to support the FDA approval.
  • Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population.

Norman S. Wright Named President and CEO of Noorda College of Osteopathic Medicine

Retrieved on: 
Friday, January 14, 2022 - 6:01pm
Nursing, Education, Health, Hospitals, Continuing, University, Training, Noorda College of Osteopathic Medicine, University, Doctor of Philosophy, Osteopathic medicine in the United States, UNC-Chapel Hill Master of Public Administration, Utah Valley University, Commission on Osteopathic College Accreditation, Knowledge, Director, Brigham Young University, Wharton School of the University of Pennsylvania, Board of directors, Student, Leadership, Economics, Health, Trustee, Industry, Awareness, Accreditation, Commission, Faculty, Education, Master of Arts, Business, Board, Woman, Management, Medicine

The Noorda College of Osteopathic Medicine (Noorda-COM) Board of Trustees has selected Norman S. Wright, Ph.D., to serve as president and chief executive officer of the college following a national search.

Key Points: 
  • The Noorda College of Osteopathic Medicine (Noorda-COM) Board of Trustees has selected Norman S. Wright, Ph.D., to serve as president and chief executive officer of the college following a national search.
  • The Noorda College of Osteopathic Medicine is fortunate to have someone with Dr. Wrights unique set of skills and experience as its next president, said Francis Gibson, chair of the board of trustees of the college.
  • I am deeply honored to have been chosen to lead the Noorda College of Osteopathic Medicine at such a critical time in higher education, said Wright.
  • Located in Provo, Utah, Noorda College of Osteopathic Medicine (Noorda-COM) offers an innovative and unique approach to medical education.

Recovery Ways Family of Programs Expands Into Houston, Texas

Retrieved on: 
Friday, January 14, 2022 - 3:00pm
California School of Professional Psychology, Doctor of Philosophy, Brain damage, Patient, Associate, Stroke, Rehabilitation, National, Blue Cross Blue Shield Association, Population, Grief, Adult, Addiction, Behavioral medicine, Chronic pain, Psychotherapy, Anxiety, Center, Bariatric surgery, Texas A&M University, Infertility, Lists of diseases, Quality of life, LPC, SALT, SJN, DRS, Medicine

Our evidence-based programs are delivered across the entire continuum of care to improve and restore quality of life for individuals and their families.

Key Points: 
  • Our evidence-based programs are delivered across the entire continuum of care to improve and restore quality of life for individuals and their families.
  • The Recovery Ways Family of Programs, that was established in 2021, consists of Washington based Breakthrough Recovery, Colonial Clinic, Alpine Recovery, Texas based Omega Recovery, Recovery Ways Idaho, and Recovery Ways Nevada.
  • We are pleased to announce that Stuart J. Nathan and Associates, in Houston, Texas, has joined the Recovery Ways Family of Programs.
  • "Stuart J. Nathan and Associates are an ideal fit with the strong clinical programs in the Recovery Ways Family of Programs.

OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members

Retrieved on: 
Friday, January 14, 2022 - 7:00am
Medicine, Patient, Research, Financial Oversight and Management Board for Puerto Rico, Supervisory board, Drug discovery, Van Lanschot Kempen, Chief scientific officer, R, UCB, Corporation, RNA, Radboud University Nijmegen, Knowledge, Gilead Sciences, CEO, Roche, National Institute, Review, Medical University of Lublin, Paul, European Society of Gynaecological Oncology, Industry, Therapy, Pharmacology, Company, Drug development, University of Antwerp, Doctor of Philosophy, Kempen, Foundation for the National Institutes of Health, RNA transfection, Neurology, Director, University, Board, Investment, Medical school, Pharmaceutical industry, Fine chemical, Galápagos Islands

These appointments bring considerable international experience to the Company across all stages of drug development as well as in finance and business development.

Key Points: 
  • These appointments bring considerable international experience to the Company across all stages of drug development as well as in finance and business development.
  • Marcin Szumowski, Co-founder & CEO, commented, "We arepleased towelcome Nancy, Paul and Rafal as new members to the Supervisory Board.
  • Together, they bring a deep understanding of medicine and extensive global experience in drug and business development.
  • Dr Van Osselaer is an experienced global biopharmaceutical professional with over 25 years experience leading drug development projects at leading pharmaceutical companies.